U.S. markets closed
  • S&P 500

    4,471.37
    +33.11 (+0.75%)
     
  • Dow 30

    35,294.76
    +382.20 (+1.09%)
     
  • Nasdaq

    14,897.34
    +73.91 (+0.50%)
     
  • Russell 2000

    2,265.65
    -8.52 (-0.37%)
     
  • Crude Oil

    82.66
    +1.35 (+1.66%)
     
  • Gold

    1,768.10
    -29.80 (-1.66%)
     
  • Silver

    23.35
    -0.13 (-0.54%)
     
  • EUR/USD

    1.1606
    +0.0005 (+0.05%)
     
  • 10-Yr Bond

    1.5760
    +0.0570 (+3.75%)
     
  • GBP/USD

    1.3751
    +0.0074 (+0.54%)
     
  • USD/JPY

    114.2000
    +0.5230 (+0.46%)
     
  • BTC-USD

    61,025.09
    +1,251.42 (+2.09%)
     
  • CMC Crypto 200

    1,464.06
    +57.32 (+4.07%)
     
  • FTSE 100

    7,234.03
    +26.32 (+0.37%)
     
  • Nikkei 225

    29,068.63
    +517.70 (+1.81%)
     

RAPT Therapeutics Reports Second Quarter 2020 Financial Results

  • Oops!
    Something went wrong.
    Please try again later.
·6 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent operational and business progress.

“We remain on track to report initial results from our Phase 1/2 trial of FLX475 later this year and to report results from our Phase 1b study of RPT193 in patients with atopic dermatitis by year end,” said Brian Wong, M.D., Ph.D., President and CEO of RAPT Therapeutics. “We are pleased with the progress we are making in moving our programs forward and adapting our organization in the face of the COVID-19 pandemic.”

Financial Results for the Second Quarter and Six Months Ended June 30, 2020

Second Quarter Ended June 30, 2020
Net loss for the second quarter of 2020 was $12.4 million, compared to $10.6 million for the second quarter of 2019.

Research and development expenses for the second quarter of 2020 were $11.0 million, compared to $8.3 million for the same period in 2019 due to increased clinical costs for FLX475 and RPT193 as well as increased personnel costs associated with these studies and stock-based compensation expenses, offset by a decrease in lab supplies used for preclinical research.

General and administrative expenses for the second quarter of 2020 were $2.8 million, compared to $2.7 million for the same period of 2019. The slight increase was primarily due to an increase in stock-based compensation expense and costs associated with our public company status, offset by a decrease in professional fees.

Six Months Ended June 30, 2020
Net loss for the six months ended June 30, 2020 was $25.5 million, compared to $19.8 million for the same period in 2019.

Research and development expenses for the six months ended June 30, 2020 were $21.7 million, compared to $16.1 million for the same period in 2019. The increase was primarily due to increases in costs relating to the clinical development of FLX475 and RPT193 and increased preclinical program costs as well as increased stock-based compensation and personnel expenses, offset by decreases in costs relating to lab supplies used for preclinical research.

General and administrative expenses for the six months ended June 30, 2020 were $6.1 million, compared to $4.4 million for the same period of 2019. The increase in general and administrative expenses was primarily due to increased stock-based compensation expense as well as costs associated with our public company status, offset by a decrease in travel and personnel costs.

As of June 30, 2020, we had cash and cash equivalents and marketable securities of $133.0 million.

About RAPT Therapeutics, Inc.
RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary discovery and development engine, the Company is developing highly selective small molecules designed to modulate the critical immune drivers underlying these diseases. RAPT has discovered and advanced two unique drug candidates, FLX475 and RPT193, each targeting C-C motif chemokine receptor 4 (CCR4), for the treatment of cancer and inflammation, respectively. The Company is also pursuing a range of targets, including hematopoietic progenitor kinase 1 (HPK1) and general control nonderepressible 2 (GCN2), that are in the discovery stage of development.

Forward-Looking Statements
This press release contains forward-looking statements. These statements relate to future events and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future performances or achievements expressed or implied by the forward-looking statements. Each of these statements is based only on current information, assumptions and expectations that are inherently subject to change and involve a number of risks and uncertainties. Forward-looking statements include, but are not limited to, statements about clinical development progress and the timing of results from clinical trials of FLX475 and RPT193. Detailed information regarding risk factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release may be found in RAPT’s Form 10-Q filed with the Securities and Exchange Commission on August 13, 2020 and subsequent filings made by RAPT with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. RAPT disclaims any obligation to update these forward-looking statements.

RAPT Media Contact:
Angela Bitting
media@rapt.com
(925) 202-6211

RAPT Investor Contact:
Sylvia Wheeler
swheeler@wheelhouselsa.com


RAPT THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(In thousands, except share and per share data)

(Unaudited)

Three Months Ended

Six Months Ended

June 30,

June 30,

2020

2019

2020

2019

Revenue

$

1,277

$

$

2,212

$

Operating expenses:

Research and development

10,986

8,267

21,669

16,137

General and administrative

2,802

2,692

6,091

4,366

Total operating expenses

13,788

10,959

27,760

20,503

Loss from operations

(12,511

)

(10,959

)

(25,548

)

(20,503

)

Other income, net

391

333

526

689

Net loss before taxes

(12,120

)

(10,626

)

(25,022

)

(19,814

)

Provision for income taxes

267

504

Net loss

(12,387

)

(10,626

)

(25,526

)

(19,814

)

Other comprehensive income (loss):

Foreign currency translation adjustment

(199

)

2

5

2

Unrealized gain on marketable securities

369

152

Total comprehensive loss

$

(12,217

)

$

(10,624

)

$

(25,369

)

$

(19,812

)

Net loss per share, basic and diluted

$

(0.51

)

$

(14.78

)

$

(1.08

)

$

(28.80

)

Weighted average number of shares used in computing net loss per share, basic and diluted

24,336,102

719,026

23,743,058

687,870


RAPT THERAPEUTICS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(In thousands)

June 30,

December 31,

2020

2019

Assets

Current assets:

Cash and cash equivalents

$

28,957

$

77,383

Marketable securities

103,993

Prepaid expenses and other current assets

3,127

3,123

Total current assets

136,077

80,506

Property and equipment, net

3,210

3,707

Other assets

389

389

Total assets

$

139,676

$

84,602

Liabilities and stockholders' equity

Current liabilities:

Accounts payable

$

2,381

$

1,143

Accrued expenses

4,256

3,642

Deferred revenue

6,013

4,000

Other current liabilities

430

471

Total current liabilities

13,080

9,256

Deferred rent, net of current portion

2,210

2,225

Deferred revenue, non-current

1,775

Commitments

Stockholders' equity:

Preferred stock

Common stock

2

2

Additional paid-in capital

309,908

235,049

Accumulated other comprehensive income

177

20

Accumulated deficit

(187,476

)

(161,950

)

Total stockholders' equity

122,611

73,121

Total liabilities and stockholders' equity

$

139,676

$

84,602